SCHEMBL4408698

SCHEMBL4408698

O=c1oc(CCl)nc2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ELANE P08246 17/20 0.70
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
C1R P00736 2/20 0.59
PDE10A Q9Y233 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692733 0.85 ELANE (0.81) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL6136297 0.85 ELANE (0.83) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL29405904 0.85 ELANE (0.81) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL1038894 0.83 ELANE (0.68) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL2812822 0.82 ELANE (0.76) ELANEMEN1KMT2AC1R
SCHEMBL29444886 0.82 ELANE (0.76) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL10550516 0.82 ELANE (1.00) ELANEMEN1KMT2AC1R
SCHEMBL692829 0.82 ELANE (0.76) ELANEMEN1KMT2AC1RPDE10A
SCHEMBL6262346 0.81 ELANE (1.00) ELANEMEN1KMT2AC1R
SCHEMBL2572932 0.81 ELANE (0.73) ELANEMEN1KMT2AC1RPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319661-B2 Polycyclic compound EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) 2025-06-03 US disclosed
CN-115745970-B Polycyclic compound, preparation method and membrane 江苏裕事达新材料科技有限责任公司 2024-12-13 CN disclosed
CN-111285853-B Polycyclic compound 江苏裕事达新材料科技有限责任公司 2023-07-28 CN disclosed
CN-115745970-A Polycyclic compound, preparation method and film 江苏裕事达新材料科技有限责任公司 2023-03-07 CN disclosed
US-20220017474-A1 Novel Polycyclic Compound EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) 2022-01-20 US disclosed
EP-3896067-A1 NOVEL POLYCYCLIC COMPOUND Eutec New Materials Technology (Suzhou) Co., Ltd (CN) 2021-10-20 EP disclosed
WO-2020118933-A1 NOVEL POLYCYCLIC COMPOUND 优缔新材料科技(苏州)有限公司 2020-06-18 WO disclosed
CN-111285853-A Novel polycyclic compound 优缔新材料科技(苏州)有限公司 2020-06-16 CN disclosed
US-8518959-B2 Quinoxaline derivatives as antitumor agents PROLEXYS PHARMACEUTICALS, INC. (US) 2013-08-27 US disclosed
US-8518959-B2 Quinoxaline derivatives as antitumor agents PROLEXYS PHARMACEUTICALS, INC. (US) 2013-08-27 US disclosed
US-7615554-B2 Erastin and erastin binding proteins, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2009-11-10 US disclosed
US-7615554-B2 Erastin and erastin binding proteins, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2009-11-10 US disclosed
US-20090214465-A1 Quinoxaline Derivatives as Antitumor Agents PROLEXYS PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
US-20090214465-A1 Quinoxaline Derivatives as Antitumor Agents PROLEXYS PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
US-20090214465-A1 Quinoxaline Derivatives as Antitumor Agents PROLEXYS PHARMACEUTICALS, INC. (US) 2009-08-27 US disclosed
WO-2008013840-A2 ERASTIN ANALOGS AND USES THEREOF TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-01-31 WO disclosed
US-20070161644-A1 Erastin analogs and uses thereof STOCKWELL BRENT R 2007-07-12 US disclosed
US-20070161644-A1 Erastin analogs and uses thereof STOCKWELL BRENT R 2007-07-12 US disclosed
US-20070161644-A1 Erastin analogs and uses thereof STOCKWELL BRENT R 2007-07-12 US disclosed
US-20060211683-A1 Erastin and erastin binding proteins, and uses thereof PROLEXYS PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161644-A1 Erastin analogs and uses thereof ERAP2, ERAP1, ERAL1 ELANE 229/4885MEN1 397/4885KMT2A 3738/4885
US-20060211683-A1 Erastin and erastin binding proteins, and uses thereof VDAC3, ERAL1, VDAC2 ELANE 2327/4885MEN1 2995/4885KMT2A 4378/4885
US-12319661-B2 Polycyclic compound CUTA, CDH1, DSG1 ELANE 3050/4885MEN1 485/4885KMT2A 3118/4885
US-20220017474-A1 Novel Polycyclic Compound CUTA, DSG1, UACA ELANE 3327/4885MEN1 639/4885KMT2A 2775/4885
US-20090214465-A1 Quinoxaline Derivatives as Antitumor Agents VDAC3, VDAC2, VDAC1 ELANE 3398/4885MEN1 2178/4885KMT2A 3575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.